Ascendiant Capital Markets Cuts Aclarion (NASDAQ:ACON) Price Target to $1.30

Aclarion (NASDAQ:ACON) had its price target decreased by Ascendiant Capital Markets from $1.50 to $1.30 in a research report released on Wednesday morning,Benzinga reports. Ascendiant Capital Markets currently has a buy rating on the stock.

Aclarion Price Performance

Aclarion stock opened at $0.18 on Wednesday. The stock’s 50 day moving average is $0.18 and its 200-day moving average is $0.24. Aclarion has a 12 month low of $0.16 and a 12 month high of $7.40.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aclarion stock. Virtu Financial LLC bought a new position in shares of Aclarion, Inc. (NASDAQ:ACON) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 115,183 shares of the company’s stock, valued at approximately $38,000. Virtu Financial LLC owned 1.40% of Aclarion at the end of the most recent reporting period. Institutional investors and hedge funds own 7.52% of the company’s stock.

Aclarion Company Profile

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.